Chronic kidney disease
Not yet recruitingPhase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4
Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4
- Disease:Chronic kidney disease
- Substances:BalcinrenoneDapagliflozin
Poland- Participants:18–64 years · 65+ years
- Substances:Balcinrenone
- Sponsor:AstraZeneca AB



